Metastatic urothelial carcinoma harboring ERBB2/3 mutations dramatically respond to chemotherapy plus anti-PD-1 antibody:A case report  

作　　者：Fei-Fei Yan Qi Jiang Bin Ru Xiao-Jie Fei Jian Ruan Xiao-Chen Zhang 

机构地区：[1]Department of Medical Oncology,the First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310000,Zhejiang Province,China [2]Department of Pain Medicine,Zhejiang Provincial People’s Hospital,Hangzhou 310000,Zhejiang Province,China [3]Department of Surgical Oncology,the First Affiliated Hospital,Zhejiang University School of Medicine Hangzhou 313000,Zhejiang Province,China [4]Department of Medical Oncology,the First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2022年第8期2497-2503,共7页世界临床病例杂志

基　　金：Supported by the Zhejiang Medical Association;No. 2018ZYC-A18

摘　　要：BACKGROUND Immune checkpoint inhibitors(ICIs)targeting the programmed death(PD)-1 pathway have substantially changed the clinical management of metastatic urothelial carcinoma(m UC);however,the response rate remains low.There are ongoing efforts to identify robust biomarkers that can effectively predict the treatment response to ICIs.Previous studies have suggested that ERBB2/3 mutations are associated with the efficacy of ICIs in gallbladder carcinoma.CASE SUMMARY We present a 59-year-old man with m UC harboring ERBB2/3 mutations(in-frame insertion of ERBB2 and ERBB3 amplification),negative PD-ligand 1 expression,and low tumor mutation burden.He received anti-PD-1 antibodies and paclitaxel as second-line treatment.After two cycles of treatment,the lung metastases had significantly shrunk,achieving good partial remission.After six cycles of combination therapy,the patient received sindilimab 200 mg once every 3 wk as maintenance monotherapy.At the last follow-up,the patient continued to exhibit a partial response and progression-free survival for as long as 19 mo.CONCLUSION ERBB2/3 mutations may represent a predictive biomarker for selecting a subgroup of m UC patients who will benefit from ICIs.

关 键 词：Urothelial carcinoma Bladder cancer ERBB Programmed death Sindilimab Case report 

分 类 号：R737.1[医药卫生—肿瘤]